Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study

NCT02219165 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Toxic Shock Syndrome

Interventions

DRUG: Intravenous human immunoglobulin
DRUG: Albumin

Sponsor

Hospices Civils de Lyon